• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bayer A G Ord (OP:BAYZF)

    54.14 -1.10 (-1.99%)
    Streaming Delayed Price Updated: 9:30 AM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 252
    Open 55.24
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 55.24
    Today's Range 54.14 - 54.14
    52wk Range 29.16 - 61.38
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
    From Bayer
    Via Business Wire
    News headline image
    New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
    From Bayer
    Via Business Wire

    Performance

    YTD
    +20.5%
    +20.5%
    1 Month
    -7.5%
    -7.5%
    3 Month
    +20.9%
    +20.9%
    6 Month
    +1.6%
    +1.6%
    1 Year
    +69.9%
    +69.9%

    More News

    Read More
    News headline image
    Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
    From Bayer
    Via Business Wire
    News headline image
    Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
    From Bayer
    Via Business Wire
    News headline image
    The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
    From Bayer
    Via Business Wire
    News headline image
    Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart
    From Bayer
    Via Business Wire
    News headline image
    Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon
    From Bayer
    Via Business Wire
    News headline image
    Bayer and Iambic Collaborate to Advance Drug Discovery with AI
    From Bayer
    Via Business Wire
    News headline image
    Bayer Completes Acquisition of Perfuse Therapeutics
    From Bayer
    Via Business Wire
    News headline image
    Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
    From Bayer
    Via Business Wire
    News headline image
    Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business
    From Bayer
    Via Business Wire
    News headline image
    Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
    From Bayer
    Via Business Wire
    News headline image
    Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
    From Bayer
    Via Business Wire
    News headline image
    ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
    From Bayer
    Via Business Wire
    News headline image
    ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
    From Bayer
    Via Business Wire
    News headline image
    Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
    From Bayer
    Via Business Wire
    News headline image
    U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
    From Bayer
    Via Business Wire
    News headline image
    AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
    From Bayer
    Via Business Wire
    News headline image
    Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
    From Bayer
    Via Business Wire
    News headline image
    Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
    From Bayer
    Via Business Wire
    News headline image
    Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
    From Bayer
    Via Business Wire

    Frequently Asked Questions

    Is Bayer A G Ord publicly traded?
    Yes, Bayer A G Ord is publicly traded.
    What exchange does Bayer A G Ord trade on?
    Bayer A G Ord trades on the OTC Traded
    What is the ticker symbol for Bayer A G Ord?
    The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded
    What is the current price of Bayer A G Ord?
    The current price of Bayer A G Ord is 54.14
    When was Bayer A G Ord last traded?
    The last trade of Bayer A G Ord was at 08/03/26 09:30 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.